A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis
Top Cited Papers
Open Access
- 8 February 2007
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (6), 580-592
- https://doi.org/10.1056/nejmoa062382
Abstract
Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 monoclonal antibody in treating psoriasis.Keywords
This publication has 33 references indexed in Scilit:
- Interleukin 12 production by monocytes from patients with psoriasis and its inhibition by ciclosporin ABritish Journal of Dermatology, 2006
- PsoriasisNew England Journal of Medicine, 2005
- Keratotic lesions in epidermolysis bullosa simplex with mottled pigmentationJournal of the American Academy of Dermatology, 2005
- Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trialJournal of the American Academy of Dermatology, 2004
- A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasisJournal of the American Academy of Dermatology, 2004
- Mini‐review The role of interleukin‐12 in human infectious diseases: only a faint signatureEuropean Journal of Immunology, 2003
- Interleukin-12 and the regulation of innate resistance and adaptive immunityNature Reviews Immunology, 2003
- Severe Mycobacterial and Salmonella Infections in Interleukin-12 Receptor-Deficient PatientsScience, 1998
- A proinflammatory activity of interleukin 8 in human skin: expression of the inducible nitric oxide synthase in psoriatic lesions and cultured keratinocytes.The Journal of Experimental Medicine, 1996
- Modified Sequentially Rejective Multiple Test ProceduresJournal of the American Statistical Association, 1986